Current Report Filing (8-k)
2020年11月21日 - 7:00AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 20, 2020
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, no par value
|
|
AKER
|
|
The
NASDAQ Capital Market
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 20, 2020, the board of directors (the “Board”) of Akers Biosciences, Inc. (the “Company”) appointed
Joshua Silverman, a current director of the Company, as Chairman of the Board. On November 20, 2020, Christopher C. Schreiber,
the current principal executive officer and President of the Company, resigned from his position as Executive Chairman of the
Board, and the Board appointed him as Chief Executive Officer of the Company, effective November 20, 2020, with Mr. Schreiber
to continue serving as the Company’s principal executive officer and president. Mr. Schreiber’s current employment
agreement with the Company will remain in effect.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
Dated:
November 20, 2020
|
/s/
Christopher C. Schreiber
|
|
Christopher
C. Schreiber
|
|
President
and Chief Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 7 2024 まで 8 2024
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 8 2023 まで 8 2024
Real-Time news about Akers Biosciences Inc (ナスダック市場): 0 recent articles
その他のAkers Biosciences, Inc.ニュース記事